PI3K and the heterogeneity of small tumour breast cancer: Dr Sherene Loi – Jules Bordet Institute, Brussels, Belgium

Metabolism in malignant tumors: Prof Tak Mak - University of Toronto, Canada

Evidence for TORC1 activation marker as a predictive factor for everolimus: Dr Thomas Bachelot - Centre Leon Berard, France

Targeting DNA damage response and repair for triple negative breast cancer: Prof Thomas Helleday - Karolinska Institutet, Swede

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer: Prof Richard Finn - Universtity of California

Endocrine therapy and endocrine resistant breast cancer: Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Neoadjuvant therapy and PCR through chemotherapy prior to surgery: Dr Michail Ignatiadis – Jules Bordet Institute, Belgium

Endocrine therapy resistance and next generation sequencing: Prof Matthew Ellis - Washington University, USA

Highlights and goals of IMPAKT 2012: Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Targeting the PI3K/mTOR pathway: Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Overcoming drug resistance and targeting critical pathways: Dr Larry Norton – Memorial Sloan-Kettering Cancer Center, New Yor

Molecularly characterising triple negative breast cancer: Prof Jorge Reis-Filho – Jules Bordet Institute, Brussels, Belgium

Recent developments in neoadjuvant therapy: Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany

Heterogeneity of tumours and the challenges of biomarker development: Prof Giuseppe Curigliano – IEO, Milan, Italy

Minimising recurrence by using most effective treatment: Prof Fabrice Andre – Institut Gustave Roussy, Paris, France

Criteria required before implementation of whole genome arrays in clinical practice: Prof Daniel Hays - University of Michigan

Cancer genes differ in different parts of a tumour: Prof Charles Swanton - CRUK London Research Institute and UCL, UK

Prognostic significance of progesterone receptor+ tumour cells: Dr Aleix Prat - University of North Carolina

Use of metformin against breast cancer: Prof Alastair Thompson – University of Dundee, UK